Who
Luke Nathaniel Walker
Director
Company insider
Files Form 4 as: Director, Context Therapeutics; Director, Zentalis Pharmaceuticals; Chief Medical Officer, Harpoon Therapeutics; SVP, Clinical Development, Cascadian Therapeutics.
In numbers
- Trades disclosed
- 36
- Buys
- 1
- Sells
- 0
- Bought
- $25K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 18 Sep 2017
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,603 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,500 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K14,200 at $1.76 | filing |
| 4 Sep 2024filed 5 Sep 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,315 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —72,481 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,500 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeutics | SEC FORM 4 Code D | —135,000 | filing |
| 7 Jan 2024filed 9 Jan 2024 | Harpoon Therapeutics | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 26 Nov 2023filed 28 Nov 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 24 Jan 2023filed 26 Jan 2023 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 3 Oct 2022filed 4 Oct 2022 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —305,000 at $0.00 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Cascadian Therapeutics | SEC FORM 4 Code U | —10,315 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Cascadian Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Cascadian Therapeuticsoption or derivative | SEC FORM 4 Code D | —334 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Cascadian Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,250 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Luke Nathaniel Walker; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.